Why the study?
Does long-term verapamil monotherapy cause adverse metabolic or hematologic effects in patients with essential hypertension?
Does long-term verapamil monotherapy cause adverse metabolic or hematologic effects in patients with essential hypertension?
Long-term verapamil monotherapy is metabolically safe and effectively controls blood pressure in patients with essential hypertension, while potentially increasing HDL-cholesterol.
Answers are grounded in this paper and cite their sources.
Verapamil monotherapy was associated with metabolic safety in hypertension; leaves open confirmation of HDL effects and outcomes in randomized trials.
In a prospective, open study 45 patients (mean age fifty-three years) with essential hypertension were treated with verapamil for four to eight years (mean 5.3 years). Blood pressure was satisfactorily controlled (from 160/104 to 145/91) and the side effects were infrequent, mild, and often transient. Verapamil did not exert any unfavorable metabolic or hematologic effects over the years. HDL-cholesterol was moderately increased (mean 24%) and the other plasma lipids were unaffected. These data suggest that the calcium channel blocker verapamil is a metabolically safe drug to use as monotherapy in essential hypertension.
No takes yet. Share an insight, caveat, or question.
Midtbø et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: